keyword
https://read.qxmd.com/read/38530606/rebistart-adherence-of-patients-with-multiple-sclerosis-to-treatment-with-subcutaneous-interferon-beta-in-the-context-of-a-patient-support-program
#21
JOURNAL ARTICLE
Matthias Schwab, Andrew Chan, Anna-Katharina Eser, Boris Kallmann, Dieter Pöhlau, Joachim Richter, Torsten B Wagner, Christoph Grothe
INTRODUCTION: Treatment adherence is a critical success factor in the disease-modifying therapy (DMT) of multiple sclerosis (MS). The REBISTART study prospectively evaluated adherence in patients using components of a patient support program (PSP). METHODS: The 12-month non-interventional multicenter study examined the real-world adherence to subcutaneously (sc) injected interferon beta-1a (Rebif® ). Patient-assessed adherence was measured by a visual analog scale (VAS) and the Morisky Medication Adherence Scale (MMAS)...
March 26, 2024: Neurology and Therapy
https://read.qxmd.com/read/38529866/-the-effectiveness-of-tele-rehabilitation-for-patients-with-multiple-sclerosis-during-the-covid-19-pandemic-in-2020-2021-was-evaluated-in-this-study
#22
JOURNAL ARTICLE
S A Sivertseva, K S Anfilofeva, A V Zotova, V A Kazantsev, A Yu Belkina, L I Volkova, M E Guseva, A N Boyko
OBJECTIVE: To evaluate the effectiveness of telerehabilitation (TELEREBT) of patients with multiple sclerosis (MS) in the context of the coronavirus pandemic 2020-2021. MATERIAL AND METHODS: The study included 37 patients with MS who underwent a course of teleRBT. The course included 10 classes of 60 minutes for 10 days with a two-day break. Various questionnaires and scales were used to assess the effectiveness, as well as an assessment of the neurological status...
2024: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
https://read.qxmd.com/read/38529804/infectious-mononucleosis-new-concepts-in-clinical-presentation-epidemiology-and-host-response
#23
JOURNAL ARTICLE
Patrick Naughton, Frances Enright, Brigid Lucey
PURPOSE OF THE REVIEW: Infectious mononucleosis (IM) is an infectious disease that presents clinically in only a small percentage of individuals despite almost universal infection with the causative agent. Here, we review the latest concepts in the clinical presentation, epidemiology, and host response of this disease. RECENT FINDINGS: Several recently published papers/reviews describe IM as a condition caused by one of several etiologic agents including, cytomegalovirus (HHV-5), Roseola virus (HHV-6) and Toxoplasmosis amongst others; this review focuses on IM as solely caused by the human herpes virus 4 (HHV-4)...
March 27, 2024: Current Opinion in Infectious Diseases
https://read.qxmd.com/read/38529711/real-world-healthcare-cost-savings-and-reduced-relapse-rate-with-off-label-rituximab-versus-disease-modifying-treatments-approved-for-relapsing-remitting-multiple-sclerosis-a-nationwide-cost-effectiveness-study
#24
JOURNAL ARTICLE
Peter Alping, Martin Neovius, Fredrik Piehl, Thomas Frisell
OBJECTIVE: Although off-label use of rituximab is a common alternative to disease-modifying therapies (DMTs) approved for multiple sclerosis (MS) in several countries, the impact of this on treatment cost-effectiveness is not well known. METHODS: We evaluated the relative cost-effectiveness of rituximab and MS-approved DMTs in a register-based cohort study of Swedish residents with relapsing-remitting MS, aged 18-65 years, starting treatment with rituximab, natalizumab, fingolimod, or dimethyl fumarate between January 2010 and July 2016, and followed through July 2021 (n = 5,924)...
March 26, 2024: Annals of Neurology
https://read.qxmd.com/read/38529498/hb-egf-and-egf-infusion-following-cns-demyelination-mitigates-age-related-decline-in-regeneration-of-oligodendrocytes-from-neural-precursor-cells-originating-in-the-ventricular-subventricular-zone
#25
Kaveh Moradi, Stanislaw Mitew, Yao Lulu Xing, Tobias D Merson
In multiple sclerosis (MS), chronic demyelination initiated by immune-mediated destruction of myelin, leads to axonal damage and neuronal cell death, resulting in a progressive decline in neurological function. The development of interventions that potentiate remyelination could hold promise as a novel treatment strategy for MS. To this end, our group has demonstrated that neural precursor cells (NPCs) residing in the ventricular-subventricular zone (V-SVZ) of the adult mouse brain contribute significantly to remyelination in response to central nervous system (CNS) demyelination and can regenerate myelin of normal thickness...
February 28, 2024: bioRxiv
https://read.qxmd.com/read/38529430/unveiling-the-intricacies-a-comprehensive-review-of-magnetic-resonance-imaging-mri-assessment-of-t2-weighted-hyperintensities-in-the-neuroimaging-landscape
#26
REVIEW
Rishabh Dhabalia, Shivali V Kashikar, Pratap S Parihar, Gaurav V Mishra
T2-weighted hyperintensities in neuroimaging represent areas of heightened signal intensity on magnetic resonance imaging (MRI) scans, holding crucial importance in neuroimaging. This comprehensive review explores the T2-weighted hyperintensities, providing insights into their definition, characteristics, clinical relevance, and underlying causes. It highlights the significance of these hyperintensities as sensitive markers for neurological disorders, including multiple sclerosis, vascular dementia, and brain tumors...
February 2024: Curēus
https://read.qxmd.com/read/38529036/clinical-presentation-and-diagnosis-of-adult-onset-leukoencephalopathy-with-axonal-spheroids-and-pigmented-glia-a-literature-analysis-of-case-studies
#27
JOURNAL ARTICLE
Spyros Papapetropoulos, Jeffrey M Gelfand, Takuya Konno, Takeshi Ikeuchi, Angela Pontius, Andreas Meier, Farid Foroutan, Zbigniew K Wszolek
INTRODUCTION: Because adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) is a rare, rapidly progressive, debilitating, and ultimately fatal neurodegenerative disease, a rapid and accurate diagnosis is critical. This analysis examined the frequency of initial misdiagnosis of ALSP via comprehensive review of peer-reviewed published cases. METHODS: Data were extracted from a MEDLINE search via PubMed (January 1, 1980, through March 22, 2022) from eligible published case reports/series for patients with an ALSP diagnosis that had been confirmed by testing for the colony-stimulating factor-1 receptor gene ( CSF1R ) mutation...
2024: Frontiers in Neurology
https://read.qxmd.com/read/38529035/disease-modifying-therapy-in-progressive-multiple-sclerosis-a-systematic-review-and-network-meta-analysis-of-randomized-controlled-trials
#28
Xin Wu, Shixin Wang, Tao Xue, Xin Tan, Jiaxuan Li, Zhouqing Chen, Zhong Wang
BACKGROUND: Currently, disease-modifying therapies (DMTs) for progressive multiple sclerosis (PMS) are widely used in clinical practice. At the same time, there are a variety of drug options for DMTs, but the effect of the drugs that can better relieve symptoms and improve the prognosis are still inconclusive. OBJECTIVES: This systematic review aimed to evaluate the efficacy and safety of DMTs for PMS and to identify the best among these drugs. METHODS: MEDLINE, EMBASE, the Cochrane Library, and clinicaltrials...
2024: Frontiers in Neurology
https://read.qxmd.com/read/38528601/profile-and-burden-of-the-family-caregiver-the-caring-experience-in-multiple-sclerosis-an-observational-study
#29
JOURNAL ARTICLE
Michela Ponzio, Andrea Tacchino, Anna Verri, Mario Alberto Battaglia, Giampaolo Brichetto, Jessica Podda
BACKGROUND: The broad implications of caring for a family member with a chronic medical condition, such as MS, can lead caregivers to experience a high burden of care. The aim of the study was to describe profile of MS caregivers and their burden and to explore potential factors influencing this burden. METHODS: 200 family caregivers of a person with MS completed survey questionnaires across a cross-sectional study. Many information were collected: caregiver socio-demographic and health-related data, caregiving activities, knowledge of MS, coping strategies, mood, social support received and care recipient information...
March 26, 2024: BMC Psychology
https://read.qxmd.com/read/38528425/a-de-novo-frameshift-variant-in-med13-gene-in-a-patient-with-autism-spectrum-disorder-and-magnetic-resonance-imaging-abnormalities-mimicking-tuberous-sclerosis
#30
Gloria Pantalone, Maria Margherita Mancardi, Andrea Rossi, Roberta Romanelli, Elena Marasco, Marini Carla
The mediator complex subunit 13 (MED13) gene is implicated in neurodevelopmental disorders including autism spectrum disorder (ASD), intellectual disability, and speech delay with varying severity and course. Additional, extra central nervous system, features include eye or vision problems, hypotonia, congenital heart abnormalities, and dysmorphisms. We describe a 7-year- and 4-month-old girl evaluated for ASD whose brain magnetic resonance imaging was suggestive of multiple cortical tubers. The exome sequencing (ES - trio analysis) uncovered a unique, de novo, frameshift variant in the MED13 gene (c...
March 25, 2024: American Journal of Medical Genetics. Part A
https://read.qxmd.com/read/38528072/resting-state-functional-connectivity-modifications-in-monoaminergic-circuits-underpin-fatigue-development-in-patients-with-multiple-sclerosis
#31
JOURNAL ARTICLE
Monica Margoni, Paola Valsasina, Anna Bacchetti, Damiano Mistri, Paolo Preziosa, Maria A Rocca, Massimo Filippi
Dysregulation of monoaminergic networks might have a role in the pathogenesis of fatigue in multiple sclerosis (MS). We investigated longitudinal changes of resting state (RS) functional connectivity (FC) in monoaminergic networks and their association with the development of fatigue in MS. Eighty-nine MS patients and 49 age- and sex-matched healthy controls (HC) underwent neurological, fatigue, and RS functional MRI assessment at baseline and after a median follow-up of 1.3 years (interquartile range = 1...
March 25, 2024: Molecular Psychiatry
https://read.qxmd.com/read/38528018/treatment-satisfaction-with-disease-modifying-therapy-is-the-only-predictor-of-adherence-among-multiple-sclerosis-patients-from-upper-egypt
#32
JOURNAL ARTICLE
Eman M Khedr, Doaa M Mahmoud, Hussein B Hussein, Islam E L Malky, Sarah S Mostafa, Ayman Gamea
Despite the proven efficacy of the disease-modifying therapy (DMT) for multiple sclerosis (MS), the rates of non-adherence are frequently high. We aimed to evaluate the rate of non-adherence to the first DMT in Upper Egypt and identify different contributing factors. Out of 310 patients, ninety-seven adult patients with RRMS were recruited from three MS units located in Upper Egypt and were subjected to the following: complete clinical history, expanded disability status score (EDSS), Eight-item Morisky Medication Adherence Scale (MMAS-8), abbreviated Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9), Hamilton depression scale, Fatigue Severity Scale (FSS) and the Pittsburgh Sleep Quality Index (PSQI)...
March 25, 2024: Scientific Reports
https://read.qxmd.com/read/38528009/a-systematic-review-and-meta-analysis-of-socio-cognitive-impairments-in-multiple-sclerose
#33
JOURNAL ARTICLE
Mandy Roheger, Lydia Grothe, Laura Hasselberg, Matthias Grothe, Marcus Meinzer
Socio-cognitive impairment is frequent in multiple sclerosis (MS). However, little is known about the relationship between other potentially relevant clinical symptoms (i.e., cognition, depression, fatigue) and the degree of socio-cognitive impairment, and neural mechanisms underlying socio-cognitive deficits in MS. Therefore, we meta-analytically quantified socio-cognitive impairment in MS. A systematic literature search in MEDLINE Ovid, Web of Science Core Collection, CENTRAL, and PsycInfo was conducted until December 2022...
March 26, 2024: Scientific Reports
https://read.qxmd.com/read/38527450/cerebral-tau-deposition-in-co-morbid-progressive-supranuclear-palsy-and-amyotrophic-lateral-sclerosis-an-18f-flortaucipir-and-7t-mri-study
#34
JOURNAL ARTICLE
Ian Cheong, Yong Du, Gwenn Smith, Jun Hua, Xu Li, Alexander Pantelyat
Introduction Progressive supranuclear palsy (PSP) is a four-repeat tauopathy characterized by multiple clinicopathologic subtypes. Advanced neuroimaging techniques have shown an early ability to distinguish PSP subtypes non-invasively for improved diagnosis. This study utilized tau-PET imaging and MRI techniques at 7 Tesla (7T) to determine the neuroimaging profile of a participant with comorbid PSP and amyotrophic lateral sclerosis (ALS). Method [18F]-flortaucipir PET imaging was performed on one participant with PSP-ALS, one participant with typical PSP (Richardson's syndrome; PSP-RS), and 15 healthy control volunteers...
March 25, 2024: Neuro-degenerative Diseases
https://read.qxmd.com/read/38527054/the-proton-sensing-receptors-tdag8-and-gpr4-are-differentially-expressed-in-human-and-mouse-oligodendrocytes-exploring-their-role-in-neuroinflammation-and-multiple-sclerosis
#35
JOURNAL ARTICLE
Fionä Caratis, Mikołaj Opiełka, Martin Hausmann, Maria Velasco-Estevez, Bartłomiej Rojek, Cheryl de Vallière, Klaus Seuwen, Gerhard Rogler, Bartosz Karaszewski, Aleksandra Rutkowska
Acidosis is one of the hallmarks of demyelinating central nervous system (CNS) lesions in multiple sclerosis (MS). The response to acidic pH is primarily mediated by a family of G protein-coupled proton-sensing receptors: OGR1, GPR4 and TDAG8. These receptors are inactive at alkaline pH, reaching maximal activation at acidic pH. Genome-wide association studies have identified a locus within the TDAG8 gene associated with several autoimmune diseases, including MS. Accordingly, we here found that expression of TDAG8, as opposed to GPR4 or OGR1, is upregulated in MS plaques...
2024: PloS One
https://read.qxmd.com/read/38527011/natalizumab-promotes-anti-inflammatory-and-repair-effects-in-multiple-sclerosis
#36
JOURNAL ARTICLE
Ragnhild Reehorst Lereim, Petra Nytrova, Astrid Guldbrandsen, Eva Kubala Havrdova, Kjell-Morten Myhr, Harald Barsnes, Frode S Berven
BACKGROUND: Multiple sclerosis is an inflammatory and degenerative disease of the central nervous system leading to demyelination and axonal loss. Relapsing-remitting multiple sclerosis (RRMS) is commonly treated by anti-inflammatory drugs, where one of the most effective drugs to date is the monoclonal antibody natalizumab. METHODS: The cerebrospinal fluid (CSF) proteome was analyzed in 56 patients with RRMS before and after natalizumab treatment, using label-free mass spectrometry and a subset of the changed proteins were verified by parallel reaction monitoring in a new cohort of 20 patients, confirming the majority of observed changes...
2024: PloS One
https://read.qxmd.com/read/38526763/determinants-of-self-perceived-quality-of-life-in-mildly-disabled-multiple-sclerosis-patients-a-cross-sectional-study
#37
JOURNAL ARTICLE
Silvy Pilotto, Matteo Floris, Paolo Solla, Maura Pugliatti, Ignazio Roberto Zarbo
INTRODUCTION: While the determinants influencing self-perceived health-related quality of life (spHRQoL) in persons with multiple sclerosis (pwMS) and severe physical impairment have been well investigated, their impact on pwMS with mild disability is poorly addressed. We aimed to investigate possible drivers of spHRQoL among Sardinian pwMS with an EDSS lower than 2.5. METHODS: A sample of 87 fully ambulatory (EDSS < 2.5) pwMS were included after screening for major cognitive impairment...
March 25, 2024: Journal of Neurology
https://read.qxmd.com/read/38526582/myelin-oligodendrocyte-glycoprotein-antibody-disease-optic-neuritis-a-structure-function-paradox
#38
JOURNAL ARTICLE
Ruby Ross, Rachel Kenney, Laura J Balcer, Steven L Galetta, Lauren Krupp, Kimberly A O'Neill, Scott N Grossman
BACKGROUND: Myelin oligodendrocyte glycoprotein antibody disease (MOGAD) is a demyelinating disorder that most commonly presents with optic neuritis (ON) and affects children more often than adults. We report 8 pediatric patients with MOG-associated ON and characterize focal optical coherence tomography (OCT) abnormalities over time that help distinguish this condition from the trajectories of other demyelinating disorders. These OCT findings are examined in the context of longitudinal visual function testing...
March 25, 2024: Journal of Neuro-ophthalmology: the Official Journal of the North American Neuro-Ophthalmology Society
https://read.qxmd.com/read/38526462/high-efficacy-therapy-discontinuation-vs-continuation-in-patients-50-years-and-older-with-nonactive-ms
#39
JOURNAL ARTICLE
Guillaume Jouvenot, Guilhem Courbon, Mathilde Lefort, Fabien Rollot, Romain Casey, Emmanuelle Le Page, Laure Michel, Gilles Edan, Jérome de Seze, Laurent Kremer, Kevin Bigaut, Sandra Vukusic, Guillaume Mathey, Jonathan Ciron, Aurélie Ruet, Elisabeth Maillart, Pierre Labauge, Hélène Zephir, Caroline Papeix, Gilles Defer, Christine Lebrun-Frenay, Thibault Moreau, David Axel Laplaud, Eric Berger, Bruno Stankoff, Pierre Clavelou, Eric Thouvenot, Olivier Heinzlef, Jean Pelletier, Abdullatif Al-Khedr, Olivier Casez, Bertrand Bourre, Philippe Cabre, Abir Wahab, Laurent Magy, Jean-Philippe Camdessanché, Ines Doghri, Solène Moulin, Haifa Ben-Nasr, Céline Labeyrie, Karolina Hankiewicz, Jean-Philippe Neau, Corinne Pottier, Chantal Nifle, Nicolas Collongues, Anne Kerbrat
IMPORTANCE: A recent randomized clinical trial concluded that discontinuing medium-efficacy therapy might be a reasonable option for older patients with nonactive multiple sclerosis (MS), but there is a lack of data on discontinuing high-efficacy therapy (HET). In younger patients, the discontinuation of natalizumab and fingolimod is associated with a risk of rebound of disease activity. OBJECTIVE: To determine whether discontinuing HET in patients 50 years and older with nonactive MS is associated with an increased risk of relapse compared with continuing HET...
March 25, 2024: JAMA Neurology
https://read.qxmd.com/read/38526264/unraveling-the-potential-of-acute-intermittent-hypoxia-as-a-strategy-for-inducing-robust-repair-in-multiple-sclerosis
#40
JOURNAL ARTICLE
Valerie M K Verge, Nataliya Tokarska, Justin M Naniong
No abstract text is available yet for this article.
November 1, 2024: Neural Regeneration Research
keyword
keyword
44948
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.